查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085043

抗病毒藥物市場：2026-2032年全球市場預測（依適應症、藥物類別、給藥途徑、最終用戶和分銷管道分類）

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗病毒藥物市場將成長至 1,008.3 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 628.1億美元
預計年份：2026年 659.2億美元
預測年份 2032 1008.3億美元
複合年成長率 (%) 6.99%

抗病毒藥物市場正從間歇性治療轉向持續的、以監測為導向的疾病管理，涵蓋愛滋病毒、B型肝炎、C型肝炎、流感、皰疹病毒、巨細胞病毒、呼吸道融合細胞病毒和SARS- 主導-2等病毒。這種需求的促進因素包括病毒性疾病的持續負擔、免疫力缺乏人群數量的增加、旅行相關感染、人口老化以及公共衛生計畫需要快速獲得有效的口服、注射和聯合抗病毒療法。

檢驗的公共衛生數據凸顯了這些需求的規模。世界衛生組織（世衛組織）估計，到2023年，將有3,990萬人感染愛滋病毒，慢性B型肝炎和C型肝炎患者人數將分別達到約2.54億和5,000萬。世衛組織也報告稱，季節性流感每年導致約10億人感染，其中300萬至500萬例為重症病例。鑑於接受和未接受治療的人數眾多，抗病毒藥物的研發、學名藥的可及性、長效製劑、兒童製劑以及抗藥性監測仍然是藥物策略面臨的核心挑戰。

抗病毒治療格局的變革性變化

抗病毒藥物領域正經歷一場變革，治療模式從廣泛的感染後治療轉向更早期、更精準的介入。直接抗病毒藥物徹底改變了丙型肝炎的治療，整合酶抑制劑和長效療法重新定義了愛滋病治療，而口服新冠病毒抗病毒藥物則鞏固了快速啟動治療的商業性和公共衛生價值。診斷工具的普及、基因組監測和治療指南的完善也促進了更早期的治療啟動和更精準的處方指導。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進標靶識別、基於結構的藥物設計、先導化合物最佳化以及針對病毒酶、入侵蛋白和宿主因子In Silico篩檢，正在加速抗病毒藥物的發現。 AI 驅動的蛋白質建模和分子模擬縮短了初步研究所需的時間，而機器學習則有助於在進行昂貴的實驗室檢驗之前，優先篩選出具有更優療效、安全性、選擇性和藥物動力學特性的化合物。

抗病毒藥物的關鍵區域見解

亞太地區在抗病毒藥物市場中具有重要的戰略地位，這得益於其龐大的患者群體、肝炎流行率、流感季節性、不斷完善的診斷覆蓋率以及中國、印度、日本、韓國和澳洲強大的生產能力。儘管在中國生物製藥政策和印度成熟的非專利抗病毒藥物生產體系的支持下，全部區域的藥物可及性正在不斷提高，但日本、韓國和澳洲憑藉其創新療法、國家醫保報銷體系和基於診斷的處方制度，仍然是重要的市場。

該組織在主要經濟區的主要觀點

由於東協人口密度高、跨境流動頻繁、流感和登革熱監測需求旺盛，以及全民健康覆蓋（UHC）計劃的不斷擴大，該地區對抗病毒藥物生產商的重要性日益凸顯。該地區在公共採購方面需求量最大，因為價格合理的學名藥可以與針對愛滋病、肝炎、嚴重呼吸道感染疾病以及需要住院治療的病毒併發症的創新療法相結合，從而實現精準的用藥。

主要國家關於抗病毒藥物的關鍵發現

美國仍然是抗病毒藥物創新和商業化的最大中心，這得益於美國食品藥物管理局 (FDA) 的批准、美國國立衛生研究院 (NIH) 的研究經費、先進的診斷技術、臨床試驗網路以及對愛滋病毒、新冠病毒、流感、肝炎和移植相關病毒感染疾病的強勁需求。加拿大強調以指南為基礎的用藥途徑、公共保險報銷和協調的感染疾病治療，而墨西哥則透過機構採購、私營部門需求以及增加非專利抗病毒療法的供應來擴大用藥途徑。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的抗病毒藥物組合，以解決抗藥性、給藥負擔、安全性、藥物交互作用以及傳統高競爭類別之外的未滿足需求。投資應重點關注長效HIV治療方案、B型肝炎功能性治癒研究、頻譜呼吸道抗病毒藥物、免疫力缺乏患者的適應症、兒童製劑以及降低病毒逃脫風險的聯合治療策略。

調查方法

本執行摘要基於二手研究，資料來源包括世界衛生組織（WHO）、聯合國愛滋病規劃署（UNAIDS）、各國監管機構、衛生技術評估機構、政府採購文件、臨床指南出版刊物、同行檢驗資訊來源以及公共衛生監測資料集。本分析重點關注檢驗的流行病學數據、監管趨勢、治療指南、准入政策、抗藥性考慮因素以及可觀察到的行業趨勢。

結論

抗病毒藥物市場正進入一個更具策略性的階段，其特點是精準醫療、快速應對疫情、人工智慧驅動的藥物研發、抗藥性監測以及提高已驗證療法的可及性。鑑於愛滋病毒、病毒性肝炎、流感、皰疹病毒、呼吸道合胞病毒、鉅巨細胞病毒和SARS-CoV-2等病毒在全球範圍內造成的負擔依然存在，抗病毒藥物對於公共衛生和藥物創新而言無疑仍至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗病毒藥物市場：依適應症分類

  • B型肝炎
  • C型肝炎
  • 單純皰疹
  • HIV
  • 流感
  • 呼吸道融合細胞病毒

第8章：抗病毒藥物市場：依藥物類別分類

  • 融合抑制劑
  • 整合酶抑制劑
  • 非核苷類逆轉錄酶抑制劑
  • 核苷類似物
  • 蛋白酶抑制劑

第9章：抗病毒藥物市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服
  • 外用

第10章 抗病毒藥物市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院
  • 長期照護機構

第11章：抗病毒藥物市場：依分銷管道分類

  • 診所
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 抗病毒藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：抗病毒藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 抗病毒藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson Services Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market is projected to grow by USD 100.83 billion at a CAGR of 6.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.81 billion
Estimated Year [2026] USD 65.92 billion
Forecast Year [2032] USD 100.83 billion
CAGR (%) 6.99%

The antiviral drugs market is evolving from episodic treatment toward continuous, surveillance-led disease management across HIV, hepatitis B, hepatitis C, influenza, herpesviruses, cytomegalovirus, respiratory syncytial virus, and SARS-CoV-2. Demand is supported by persistent viral disease burden, expanding immunocompromised populations, travel-related transmission, aging demographics, and public health preparedness programs that require rapid access to effective oral, injectable, and combination antivirals.

Verified public health data underscore the scale of need. The World Health Organization estimates that 39.9 million people were living with HIV in 2023, while chronic hepatitis B and hepatitis C affected approximately 254 million and 50 million people, respectively. WHO also reports that seasonal influenza causes around 1 billion infections annually, including 3 million to 5 million severe cases. These large treated and untreated populations keep antiviral drug discovery, generic access, long-acting formulations, pediatric options, and resistance monitoring at the center of pharmaceutical strategy.

Transformative Shifts in the Antiviral Landscape

The antiviral landscape is being reshaped by a shift from broad post-infection treatment to earlier, precision-based intervention. Direct-acting antivirals transformed hepatitis C care, integrase inhibitors and long-acting regimens are redefining HIV treatment, and oral COVID-19 antivirals reinforced the commercial and public health value of rapidly deployable therapies. Wider diagnostic availability, genomic surveillance, and treatment guidelines are also supporting faster therapy initiation and more targeted prescribing.

Market competition is moving beyond efficacy alone. Payers, health systems, and procurement agencies are prioritizing resistance profile, dosing convenience, drug-drug interaction management, real-world outcomes, tolerability, and manufacturing resilience. As patent expiries expand generic competition in mature categories, innovation is concentrating on novel mechanisms, pan-viral platforms, host-targeted antivirals, pediatric formulations, depot delivery, and therapies for underserved viral infections.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating antiviral drug discovery by improving target identification, structure-based design, lead optimization, and in silico screening against viral enzymes, entry proteins, and host factors. AI-enabled protein modeling and molecular simulation are reducing early research timelines, while machine learning helps prioritize compounds with favorable potency, safety, selectivity, and pharmacokinetic properties before costly laboratory validation.

AI is also strengthening clinical and commercial execution. Predictive analytics can identify patient cohorts at risk of severe infection, support adaptive trial design, monitor antiviral resistance, improve safety signal detection, and optimize pharmacovigilance from real-world evidence. The cumulative impact is a more responsive antiviral ecosystem that can move faster during outbreaks while improving lifecycle management for established therapies and supporting evidence-based market access.

Key Regional Insights for Antiviral Drugs

Asia-Pacific is a strategically important antiviral drugs region, driven by large patient populations, hepatitis prevalence, influenza seasonality, rising diagnostic coverage, and strong manufacturing capacity in China, India, Japan, South Korea, and Australia. China's biopharmaceutical policy support and India's established generic antiviral production are improving regional access, while Japan, South Korea, and Australia remain important markets for innovative therapies, national reimbursement pathways, and diagnostics-linked prescribing.

North America leads in antiviral innovation, clinical trial activity, regulatory execution, and rapid adoption of novel therapies, supported by U.S. FDA pathways, public health purchasing, advanced laboratory networks, and specialty pharmacy infrastructure. Europe benefits from centralized regulatory coordination, mature reimbursement systems, antimicrobial and antiviral stewardship programs, and sustained demand across HIV, hepatitis, influenza, and hospital-based viral infections. Latin America is expanding access through public procurement and generic adoption, with Brazil and Mexico acting as major demand centers for HIV, hepatitis, respiratory infection, and immunization-linked care pathways.

The Middle East is investing in healthcare modernization, outbreak preparedness, digital health infrastructure, and specialty care capacity, particularly across Gulf markets with centralized purchasing systems. Africa remains a critical access region due to high HIV and viral hepatitis burden, where donor-supported programs, national treatment guidelines, local distribution partnerships, and affordable generics are central to treatment continuity and equitable antiviral access.

Key Group Insights Across Major Economic Blocs

ASEAN markets are increasingly important for antiviral drug manufacturers because of dense populations, cross-border mobility, influenza and dengue surveillance needs, and expanding universal health coverage initiatives. Demand is strongest where public procurement can combine affordable generics with targeted access to innovative therapies for HIV, hepatitis, severe respiratory infections, and hospital-treated viral complications.

The GCC is characterized by high healthcare spending, centralized purchasing, medical infrastructure investment, and rapid uptake of premium hospital and specialty medicines, making it attractive for novel antivirals and preparedness stockpiles. The European Union provides a harmonized regulatory environment and substantial purchasing power, but market access success depends on health technology assessment outcomes, comparative effectiveness data, budget impact review, and pricing negotiations.

BRICS countries combine large disease burden with expanding domestic pharmaceutical capabilities, creating opportunities for technology transfer, local manufacturing, clinical research, and affordable treatment scale-up. G7 countries remain core centers for antiviral research, intellectual property generation, advanced clinical adoption, and regulatory science, while NATO member states increasingly view antivirals as part of health security, pandemic preparedness, military medical readiness, and supply chain resilience strategies.

Key Country Insights in Antiviral Drugs

The United States remains the largest innovation and commercialization hub for antiviral drugs, supported by FDA approvals, National Institutes of Health research funding, advanced diagnostics, clinical trial networks, and strong demand in HIV, COVID-19, influenza, hepatitis, and transplant-related viral infections. Canada emphasizes guideline-driven access, public reimbursement, and coordinated infectious disease care, while Mexico is expanding access through institutional purchasing, private-sector demand, and growing use of generic antiviral therapies.

Brazil leads Latin American antiviral demand through large public health programs, particularly in HIV and hepatitis, while local regulatory, tendering, and pricing dynamics shape market entry. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with cost-effectiveness scrutiny; Germany and France are especially influential for evidence expectations, while the UK's National Health Service and NICE assessment processes shape value demonstration and reimbursement strategy.

Russia has domestic production priorities and demand across influenza, hepatitis, and HIV, though geopolitical and procurement factors affect international participation. In Asia-Pacific, China and India are pivotal due to scale, disease burden, and manufacturing capacity; Japan is a high-value market for innovative therapies and aging-population needs; Australia offers strong reimbursement pathways and surveillance-based public health policy; and South Korea combines advanced healthcare infrastructure, rapid diagnostics, and a growing biopharma sector.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated antiviral portfolios that address resistance, dosing burden, safety, drug-drug interactions, and unmet needs beyond crowded legacy categories. Investment should focus on long-acting HIV regimens, hepatitis B functional cure research, broad-spectrum respiratory antivirals, immunocompromised patient indications, pediatric formulations, and combination strategies that reduce viral escape.

Executives should also strengthen regional access models through tiered pricing, local manufacturing partnerships, public procurement engagement, regulatory readiness, and pharmacovigilance systems. Organizations that integrate AI-enabled discovery, real-world evidence generation, companion diagnostics, resistance surveillance, and resilient supply chains will be better positioned to compete in both routine care and outbreak-response environments.

Research Methodology

This executive summary is based on secondary research from verified public sources, including the World Health Organization, UNAIDS, national regulatory agencies, health technology assessment bodies, government procurement references, clinical guideline publications, peer-reviewed literature, and public health surveillance datasets. The analysis emphasizes validated epidemiology, regulatory trends, treatment guidelines, access policies, resistance considerations, and observable industry developments.

Insights are reviewed for consistency, relevance, and data integrity to support executive decision-making in the antiviral drugs market. The methodology excludes market sizing, market share, and forecasting, focusing instead on evidence-backed disease burden, therapeutic innovation, regional access dynamics, and strategic implications for antiviral drug development and commercialization.

Conclusion

The antiviral drugs market is entering a more strategic phase defined by precision medicine, rapid outbreak readiness, AI-supported discovery, resistance monitoring, and expanded access to proven therapies. Persistent global burdens from HIV, viral hepatitis, influenza, herpesviruses, RSV, cytomegalovirus, and SARS-CoV-2 ensure that antivirals remain essential to public health and pharmaceutical innovation.

Organizations that combine scientific differentiation with affordability, evidence generation, regulatory agility, and supply resilience will be best positioned to address evolving clinical and public health needs. The next wave of leadership will come from innovators capable of serving both high-value specialty markets and large-scale public health programs with reliable, data-driven antiviral solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antiviral Drugs Market, by Indication

  • 7.1. Hepatitis B
  • 7.2. Hepatitis C
  • 7.3. Herpes Simplex
  • 7.4. Hiv
  • 7.5. Influenza
  • 7.6. Respiratory Syncytial Virus

8. Antiviral Drugs Market, by Drug Class

  • 8.1. Fusion Inhibitors
  • 8.2. Integrase Inhibitors
  • 8.3. Non Nucleoside Reverse Transcriptase Inhibitors
  • 8.4. Nucleoside Analogues
  • 8.5. Protease Inhibitors

9. Antiviral Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Antiviral Drugs Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Long Term Care Facilities

11. Antiviral Drugs Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Antiviral Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Antiviral Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antiviral Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. AstraZeneca plc
  • 16.3. Aurobindo Pharma Limited
  • 16.4. Bayer AG
  • 16.5. Boehringer Ingelheim GmbH
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Cipla Limited
  • 16.8. Dr. Reddy's Laboratories Ltd.
  • 16.9. Gilead Sciences, Inc.
  • 16.10. GlaxoSmithKline plc
  • 16.11. Hetero Labs Limited
  • 16.12. Johnson & Johnson Services Ltd.
  • 16.13. Merck & Co., Inc.
  • 16.14. Mylan N.V.
  • 16.15. Novartis AG
  • 16.16. Pfizer Inc.
  • 16.17. Roche Holding AG
  • 16.18. Sandoz International GmbH
  • 16.19. Sanofi S.A.
  • 16.20. Sun Pharmaceutical Industries Ltd.
  • 16.21. Takeda Pharmaceutical Company Limited
  • 16.22. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HERPES SIMPLEX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HERPES SIMPLEX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HERPES SIMPLEX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FUSION INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUSION INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUSION INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEOSIDE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEOSIDE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEOSIDE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)